CoChat

Genomic surveillance reveals co-occurrence of Plasmodium falciparum drug resistance variants across diverse transmission settings in Ethiopia

Open access

The DOI matches its Crossref record; 67 of the 67 references it cites were found in a registry or an index; none of the 40 sources its claims cite is checked for support yet.

Abstract

The emergence of antimalarial drug resistance threatens malaria control and elimination efforts in Africa. Ethiopia, once a success story in case reduction, is now experiencing a resurgence. Here we examine key drug resistance genes ( Pfmdr1 , Pfcrt , Pfk13 , Pfdhfr and Pfdhps ) and mitochondrial genomes from 605 Plasmodium falciparum isolates collected across 15 districts in Ethiopia with varying transmission intensity and Plasmodium vivax co-endemicity. Although chloroquine was withdrawn for P. falciparum long ago, it remains the first-line treatment for P. vivax ; this overlapping use may shape selection pressure in co-endemic settings that influences resistance markers to artemether–lumefantrine, the current first-line therapy for P. falciparum . A dominant Pf MDR1 NFSND haplotype, associated with reduced lumefantrine susceptibility, was identified alongside near fixation of the chloroquine-resistant Pf CRT CVIET haplotype in specific areas. Concerningly, Pf K13 variants associated with partial artemisinin resistance, R622I (10%), A675V (1.7%) and P441L (1.1%), were expanding. Multilevel models demonstrated robust, independent associations of R622I with Pf CRT CVIET and Pf DHFR AICNI, while ecological predictors were weaker and less consistent. These findings highlight genetic co-occurrence of Pfcrt and Pfk13 mutations in P. vivax – P. falciparum co-endemic settings and can inform antimalarial policy in Ethiopia.

Overview

CoChat Summary

TL;DR

Genomic surveillance of 605 *Plasmodium falciparum* isolates from 15 Ethiopian districts found widespread chloroquine- and antifolate-resistance haplotypes alongside expanding PfK13 artemisinin-resistance variants. PfK13 R622I co-occurred robustly with PfCRT CVIET and PfDHFR AICNI, suggesting overlapping drug pressures in *P. vivax*–*P. falciparum* co-endemic settings.

Key findings

  • PfMDR1 NFSND, associated with reduced lumefantrine susceptibility, was dominant at 93.0% (449/483), while the chloroquine-resistant PfCRT CVIET haplotype was 61.2% (301/492) and reached fixation in Fedis and near fixation in Batu, Amibara, Fentale and Dera.
  • Despite sulfadoxine–pyrimethamine withdrawal, antifolate mutations persisted: PfDHFR AIRNI was 50.0% (245/490) and AICNI 39.6% (194/490); PfDHPS ISGEAA was 65.7% (330/502), and the quintuple PfDHFR–PfDHPS haplotype AIRNI/ISGEAA was 42.8% (194/453).
  • PfK13 artemisinin-resistance variants were detected: R622I 10.0% (57/572), A675V 1.7% (10/572) and P441L 1.1% (6/571); R622I reached 48.6% in Gondar.
  • In mixed-effects models restricted to districts with R622I circulation, R622I was independently associated with PfCRT CVIET (adjusted OR 3.19, 95% CI 1.60–6.34; P = 0.001) and PfDHFR AICNI (adjusted OR 5.16, 95% CI 1.60–16.70; P = 0.006), while ecological predictors were weaker and less consistent.

Methods

  • Nationwide genomic surveillance collected 605 symptomatic *P. falciparum* blood samples between October 2019 and January 2023 across 15 Ethiopian districts selected for diverse transmission intensity and *P. vivax* co-endemicity; after quality control, 584 isolates were retained for variant analysis.
  • Dried blood spots underwent DNA extraction and qPCR; targeted deep-amplicon sequencing covered *Pfcrt*, *Pfdhps*, *Pfmdr1*, *Pfdhfr*, *Pfk13* and the mitochondrial genome, with successful genotyping counts varying by target (for example, Pfk13 n = 575, Pfcrt n = 533, Pfmdr1 n = 556).
  • Analyses included haplotype construction, chi-squared tests, Wilson confidence intervals, Spearman correlations with bootstrap resampling, Fisher exact tests with Benjamini–Hochberg correction for co-occurrence, mixed-effects and Bayesian multilevel logistic regression, PCA, neighbour-joining trees and identity-by-descent analysis using hmmIBD.

Limitations

  • The paper states the study focused on known resistance markers in a limited set of genes, potentially overlooking novel mechanisms, and that the functional significance of observed co-occurrence patterns remains unclear, requiring causal studies.
  • The paper notes that IBD analysis was restricted to drug resistance genes and the mitochondrial genome, so genome-wide approaches are needed for more robust inference of population relatedness and gene flow; whole-genome and longitudinal data linked to clinical outcomes are also needed.
  • Evident from the text: this is targeted amplicon sequencing rather than whole-genome sequencing, sample sizes vary by locus, and the design is cross-sectional without reported treatment-efficacy outcomes.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.1038/s41564-026-02420-5

Cites

67 of 67 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Figures

Fig. 1 Map showing surveillance sites for antimalarial drug resistance (study health facilities) across Ethiopia are depicted in varying malaria transmission settings. a , A map showing study districts for antimalarial drug resistance surveillance across Ethiopia. b , The average API from 2020 to 2022, categorizing areas by transmission intensity: very low (light blue), low (dark blue), moderate (light orange) and high (orange). c , The proportion of P. vivax infections co-endemic with P. falciparum populations, with the colour scale indicating the proportion of P. vivax cases (ranging from 0% to >60%) per region. Study health facilities were chosen to represent diverse transmission conditions and P. vivax co-endemicity for robust antimalarial drug resistance surveillance. To assess disease hotspots and malaria transmission intensity, as well as characterize the distribution of P. vivax , we utilized malaria surveillance data from the Public Health Emergency Management system. The dataset covers
Fig. 1 Map showing surveillance sites for antimalarial drug resistance (study health facilities) across Ethiopia are depicted in varying malaria transmission settings. a , A map showing study districts for antimalarial drug resistance surveillance across Ethiopia. b , The average API from 2020 to 2022, categorizing areas by transmission intensity: very low (light blue), low (dark blue), moderate (light orange) and high (orange). c , The proportion of P. vivax infections co-endemic with P. falciparum populations, with the colour scale indicating the proportion of P. vivax cases (ranging from 0% to >60%) per region. Study health facilities were chosen to represent diverse transmission conditions and P. vivax co-endemicity for robust antimalarial drug resistance surveillance. To assess disease hotspots and malaria transmission intensity, as well as characterize the distribution of P. vivax , we utilized malaria surveillance data from the Public Health Emergency Management system. The dataset coversCC BY · From the PDF
Fig. 2 Geographic distribution and prevalence of Pf DHFR, Pf DHPS, Pf CRT and Pf MDR1 haplotypes and mutations in Ethiopian P. falciparum populations. a , c , e , g , Geographic distribution and proportions of observed haplotypes as pie charts are shown for Pf DHFR ( a ), Pf DHPS ( c ), Pf CRT ( e ) and Pf MDR1 ( g ). The pink colour in a and c denotes the districts represented by the
Fig. 2 Geographic distribution and prevalence of Pf DHFR, Pf DHPS, Pf CRT and Pf MDR1 haplotypes and mutations in Ethiopian P. falciparum populations. a , c , e , g , Geographic distribution and proportions of observed haplotypes as pie charts are shown for Pf DHFR ( a ), Pf DHPS ( c ), Pf CRT ( e ) and Pf MDR1 ( g ). The pink colour in a and c denotes the districts represented by theCC BY · From the PDF
Image 3
CC BY · From the PDF
Image 4
CC BY · From the PDF
Fig. 3 Prevalence, distribution and co-occurrence of P. falciparum drug resistance mutations in Ethiopia. a , Pf K13 variant prevalence, presenting all non-synonymous variants with overall frequency of >1%. Variants are labelled by WHO-validated ART-R markers (R622I and A675V), WHO candidate ART-R markers (P441L), variants not associated with ART-R (K189T, K189N and L258M) and variants unlikely to be associated with ART-R (R255K, I352T, E344D and L134V). b , The geographic distribution of Pf K13 variants. Pie charts show mutation proportions per location. R622I was most prevalent in Gondar (17/35, 48.57%). c , An upset intersection plot: co-occurrence of prevalent P. falciparum mutations. The most prevalent haplotype was Pf MDR1 NFSND ( n = 449), commonly found with Pf K13 R622I ( n = 48), A675V ( n = 10) and P441L ( n = 6). Red highlighting indicates the co-occurrence of Pf K13 variants (both the validated artemisinin resistance marker R622I and the candidate marker P441L) with the Pf CRT N326S background variant, a known facilitator of chloroquine resistance and a lumefantrine susceptibility marker. Specifically, Pf CRT N326S co-occurred with Pf K13 R622I in 45 isolates and with Pf K13 P441L in 6 isolates. Pf CRT CVIET and Pf K13 R622I were found together in 40 isolates. Notably, Pf CRT I356T and PfK13 R622I were never observed together. d , The chord diagram visualizes the pairwise co-occurrence relationships
Fig. 3 Prevalence, distribution and co-occurrence of P. falciparum drug resistance mutations in Ethiopia. a , Pf K13 variant prevalence, presenting all non-synonymous variants with overall frequency of >1%. Variants are labelled by WHO-validated ART-R markers (R622I and A675V), WHO candidate ART-R markers (P441L), variants not associated with ART-R (K189T, K189N and L258M) and variants unlikely to be associated with ART-R (R255K, I352T, E344D and L134V). b , The geographic distribution of Pf K13 variants. Pie charts show mutation proportions per location. R622I was most prevalent in Gondar (17/35, 48.57%). c , An upset intersection plot: co-occurrence of prevalent P. falciparum mutations. The most prevalent haplotype was Pf MDR1 NFSND ( n = 449), commonly found with Pf K13 R622I ( n = 48), A675V ( n = 10) and P441L ( n = 6). Red highlighting indicates the co-occurrence of Pf K13 variants (both the validated artemisinin resistance marker R622I and the candidate marker P441L) with the Pf CRT N326S background variant, a known facilitator of chloroquine resistance and a lumefantrine susceptibility marker. Specifically, Pf CRT N326S co-occurred with Pf K13 R622I in 45 isolates and with Pf K13 P441L in 6 isolates. Pf CRT CVIET and Pf K13 R622I were found together in 40 isolates. Notably, Pf CRT I356T and PfK13 R622I were never observed together. d , The chord diagram visualizes the pairwise co-occurrence relationshipsCC BY · From the PDF
Image 6
CC BY · From the PDF
Image 7
CC BY · From the PDF
Extended Data Fig. 1 | Cluster heatmap representing the frequency of
Extended Data Fig. 1 | Cluster heatmap representing the frequency ofCC BY · From the PDF
Extended Data Fig. 2 | Cluster heatmap representing log-transformed
Extended Data Fig. 2 | Cluster heatmap representing log-transformedCC BY · From the PDF
Image 10
CC BY · From the PDF
Extended Data Fig. 4 | Geographic distribution and prevalence of combined
Extended Data Fig. 4 | Geographic distribution and prevalence of combinedCC BY · From the PDF
A) PfDHFR
A) PfDHFRCC BY · From the PDF
Image 13
CC BY · From the PDF
Extended Data Fig. 6 | Correlation between haplotypes and the Annual Parasite Index (API) and the proportion of P. vivax infections. Bubble
Extended Data Fig. 6 | Correlation between haplotypes and the Annual Parasite Index (API) and the proportion of P. vivax infections. BubbleCC BY · From the PDF
Image 15
CC BY · From the PDF
Extended Data Fig. 8 | Principal Component Analysis (PCA) of mitochondrial genome. Plots include isolates collected in this study ( A -D ), coloured by district of origin ( A -B ) or the proportion of P. vivax to P. falciparum infections in the
Extended Data Fig. 8 | Principal Component Analysis (PCA) of mitochondrial genome. Plots include isolates collected in this study ( A -D ), coloured by district of origin ( A -B ) or the proportion of P. vivax to P. falciparum infections in theCC BY · From the PDF

Verification

Claims the paper makes

0 Valid · 0 Not valid · 15 Not checked · 100 Own results and interpretations

40 more claims

Create a free account to see all 115 claims and to verify the 40 references still open.

See all claims — free account
  • It may state two separate claims as one. 51
  • Probably not a substantial claim. 24

Create a free account to see these claims.

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

Each contradiction between two passages listed here was confirmed by an independent check.

4 of 4

Citations

Cites

Show all 67 references

Cited by

See all 4

Metadata

Authors
Letebo, A., Vanheer, L. N., Engdaw, M., Ejigu, L. A., Hailu Alemayehu, D., Deressa, J. D., Adnew, B., Ayele, A., Bezabih, M. K., Demisse, M., Seyoum, T., Shiferaw, M., Sime, H., Weldemariam, A. G., Shimelash, A., Tafa, E. B., Chali, W., Alemayehu, L., Kassa, F. A., Zeleke, A. J., Hamza, T. A., Tamirat, A. B., Misganaw, T., Bogale, A., Abriham, Z. Y., Nasir, Y., Jebessa, G., Yohannes, M., Kebede, B. A., Ayele, M. K., Abdo, M., Habtamu, G., Gizat, A., Phelan, J., Matlock, B., Fidock, D. A., Campino, S., Assefa, A., Koepfli, C., Massebo, F., & Tadesse, F. G.
Affiliations
  • Armauer Hansen Research Institute (ET)
  • London School of Hygiene & Tropical Medicine (GB)
  • Radboud University Medical Center (NL)
  • Ethiopian Public Health Institute (ET)
  • Madda Walabu University (ET)
  • Woldia University (ET)
  • Dilla University (ET)
  • Oak Ridge Institute for Science and Education (US)
  • Columbia University Irving Medical Center (US)
  • University of North Carolina at Chapel Hill (US)
  • University of Notre Dame (US)
  • Arba Minch University (ET)
Corresponding author
Tadesse, Fitsum G.
Venue
Nature Microbiology
Published
2026-08-05
Volume
11
Issue
9
Pages
2577-2588
ISSN
2058-5276 (ISSN-L)
OpenAlex
W7172534540
Cited by
4
References
66
Citations by year
2026: 4
FWCI
14.78
Type
journal article
Language
en
Open access
Licence
Locations
  • Nature Microbiology (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • LSHTM Research Online (London School of Hygiene and Tropical Medicine) (acceptedVersion)
  • Radboud Repository (Radboud University) (submittedVersion)
Funders
  • Bill and Melinda Gates Foundation (INV-005898; INV-035257; INV-048214, INV-005898)
  • Wellcome Trust (102348)
  • Foundation for the National Institutes of Health (R01 AI050234 and R01 AI109023, AI178183)
Topics
  • Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Malaria Research and Control
  • Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmacology › Pharmacogenetics and Drug Metabolism
  • Health Sciences › Medicine › Microbiology (medical) › Antibiotic Resistance in Bacteria
Keywords
Plasmodium falciparum, antimalarial drug resistance, pfmdr1, pfcrt, pfk13, pfdhfr, pfdhps, mitochondrial genome, artemisinin resistance, artemether-lumefantrine, chloroquine resistance, transmission intensity, Ethiopia, malaria resurgence
MeSH terms
Artemether, Lumefantrine Drug Combination, Antimalarials, Chloroquine, Drug Resistance, Ethiopia, Haplotypes, Humans, Plasmodium falciparum, Plasmodium vivax, Protozoan Proteins, Malaria, Falciparum, Genome, Mitochondrial

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

A language model drew the claims from the paper on 2026-11-21, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-11-21 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Genomic surveillance reveals co-occurrence of Plasmodium falciparum drug resistance variants across diverse transmission settings in Ethiopia. https://app.cochat.ai/papers/10.1038/s41564-026-02420-5
The paper
Letebo, A., Vanheer, L. N., Engdaw, M., Ejigu, L. A., Hailu Alemayehu, D., Deressa, J. D., Adnew, B., Ayele, A., Bezabih, M. K., Demisse, M., Seyoum, T., Shiferaw, M., Sime, H., Weldemariam, A. G., Shimelash, A., Tafa, E. B., Chali, W., Alemayehu, L., Kassa, F. A., . . . Tadesse, F. G. (2026). Genomic surveillance reveals co-occurrence of Plasmodium falciparum drug resistance variants across diverse transmission settings in Ethiopia. Nature Microbiology. https://doi.org/10.1038/s41564-026-02420-5

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.